These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 2922053)

  • 41. Catalytic antibodies for complex reactions: hapten design and the importance of screening for catalysis in the generation of catalytic antibodies for the NDA/CN reaction.
    DeSilva BS; Orosz G; Egodage KL; Carlson RG; Schowen RL; Wilson GS
    Appl Biochem Biotechnol; 2000; 83(1-3):195-206; discussion 206-8, 297-313. PubMed ID: 10826960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural basis for antibody catalysis of a cationic cyclization reaction.
    Zhu X; Heine A; Monnat F; Houk KN; Janda KD; Wilson IA
    J Mol Biol; 2003 May; 329(1):69-83. PubMed ID: 12742019
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A catalytic antibody against a tocopherol cyclase inhibitor.
    Manetsch R; Zheng L; Reymond MT; Woggon WD; Reymond JL
    Chemistry; 2004 May; 10(10):2487-506. PubMed ID: 15146522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Catalytic antibodies: generation of a new class of protein catalysts exploiting the immune system].
    Fujii I
    Yakugaku Zasshi; 1996 Aug; 116(8):606-21. PubMed ID: 8831262
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel reactions catalysed by antibodies.
    Golinelli-Pimpaneau B
    Curr Opin Struct Biol; 2000 Dec; 10(6):697-708. PubMed ID: 11114507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amino acid sequences and hapten binding of catalytic and noncatalytic antibodies against N(alpha)-(5'-phosphopyridoxyl)-L-lysine.
    Mouratou B; Gramatikova S; Kunz B; Christen P
    Mol Immunol; 2000 Aug; 37(11):633-40. PubMed ID: 11164891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Catalytic antibody and its medical applications].
    Fujii I; Iwabuchi Y
    Nihon Rinsho; 1995 Feb; 53(2):518-27. PubMed ID: 7699882
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody-combining sites: prediction and design.
    Gregory DS; Staunton D; Martin AC; Cheetham JC; Pedersen J; Rees AR
    Biochem Soc Symp; 1990; 57():147-55. PubMed ID: 2099739
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Conformational effects in biological catalysis: an antibody-catalyzed oxy-cope rearrangement.
    Mundorff EC; Hanson MA; Varvak A; Ulrich H; Schultz PG; Stevens RC
    Biochemistry; 2000 Feb; 39(4):627-32. PubMed ID: 10651626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and syntheses of three haptens to generate catalytic antibodies that cleave amide bonds with nucleophilic catalysis.
    Ersoy O; Fleck R; Blanco MJ; Masamune S
    Bioorg Med Chem; 1999 Feb; 7(2):279-86. PubMed ID: 10218819
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoclonal antibodies as catalysts and templates for organic chemical reactions.
    Green BS
    Adv Biotechnol Processes; 1989; 11():359-93. PubMed ID: 2644946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of flexible and constrained haptens in eliciting antibody catalysts for paraoxon hydrolysis.
    Spivak DA; Hoffman TZ; Moore AH; Taylor MJ; Janda KD
    Bioorg Med Chem; 1999 Jun; 7(6):1145-50. PubMed ID: 10428386
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody catalysis via strategic use of haptenic charge.
    Kikuchi K; Hilvert D
    Acta Chem Scand (Cph); 1996 Apr; 50(4):333-6. PubMed ID: 8639376
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Catalytic antibody activity elicited by active immunisation. Evidence for natural variation involving preferential stabilization of the transition state.
    Gallacher G; Jackson CS; Searcey M; Goel R; Mellor GW; Smith CZ; Brocklehurst K
    Eur J Biochem; 1993 May; 214(1):197-207. PubMed ID: 8508792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A bait and switch hapten strategy generates catalytic antibodies for phosphodiester hydrolysis.
    Wentworth P; Liu Y; Wentworth AD; Fan P; Foley MJ; Janda KD
    Proc Natl Acad Sci U S A; 1998 May; 95(11):5971-5. PubMed ID: 9600901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemical equilibrium at an antibody binding site: catalytic efficiency defined by a Haldane relationship.
    Janjić N; Tramontano A
    Biochemistry; 1990 Sep; 29(37):8867-72. PubMed ID: 2271563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An unexpectedly efficient catalytic antibody operating by ping-pong and induced fit mechanisms.
    Wirsching P; Ashley JA; Benkovic SJ; Janda KD; Lerner RA
    Science; 1991 May; 252(5006):680-5. PubMed ID: 2024120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evidence that the mechanism of antibody-catalysed hydrolysis of arylcarbamates can be determined by the structure of the immunogen used to elicit the catalytic antibody.
    Boucher G; Said B; Ostler EL; Resmini M; Brocklehurst K; Gallacher G
    Biochem J; 2007 Feb; 401(3):721-6. PubMed ID: 17020536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. alpha-Mannosidase activity from antibody raised against a glucal antigen.
    Yu J
    Bioorg Med Chem Lett; 1998 May; 8(10):1145-8. PubMed ID: 9871724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Catalytic properties and immunoprecipitation of beta-glucuronidase in presence of its IgG and Fab fragments: identification of antigenic domains.
    Gupta GS; Singh G
    Indian J Biochem Biophys; 1988 Aug; 25(4):319-25. PubMed ID: 2467874
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.